Clinical Trial Search

Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…

Primary: Median Percent Change From Baseline in Average Walking Speed on Timed 25-Foot Walk Test — 1.2; 7.5; 9.7; 6.9 percent change

Primary: Assess the Effect of NBT-NM108 on Serum TNF-alpha Levels in MS Patients — 25.62; 22.58; 20.73 pg/ml

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Number of Adverse Events Assessed by CTCAE v4.0 — 5; 0 total events

Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF

Primary: Kinematics — 15.5; 10 degrees

Primary: Modified Fatigue Impact Scale — 46.1; 46.7 units on a scale — p=.64

Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci

Primary: No.of Gd+ Lesions From Week 8 to Week 24 — 46; 33; 5; 13 participants — p=0.04

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale

Primary: Neuro-cognitive Competence in Daily Living - California Verbal Learning Test-II — 56.1; 53.6 units on a scale — p=0.926

Primary: Fatigue — 21; 24 % decline

Primary: Event-Free Survival Probability During the 5 Years After Transplant — 0.692 Probability

Primary: Safety and Tolerability — 21; 22 participants

Primary: Cerebral Metabolic Rate of Oxygen (CMRO2) — 165.84; 128.3; 159.4 µmol/100g/min

Primary: Proportion of Subjects That Experience a Relapse — 0.32; 0.34 proportion of participants — p=0.60

Primary: Adherence — 2; 6; 10; 12 Participants

Primary: Change From Baseline in the Average Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) Over On-treatment Scans — 7.4; -2.4 lesions

Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028

Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672

Primary: Change in Cortical Activation — 0.054; -0.024; 0.074; -0.016 Unitless GLM beta weight (HbO) — p=0.007

Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51

Primary: Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion Over the Course of the Study Duration — 6; 16 Participants — p=0.521

Primary: Mean Preload Phase Duration (PLD) — 0.152; 0.238; 0.163; 0.202 seconds

Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0

Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale

Primary: ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living) — 3.1; 4.9 score on a scale — p=0.003